Natalizumab: differenze tra le versioni

Contenuto cancellato Contenuto aggiunto
Riga 25:
*Sheremata WA et al: ''A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.'' Neurology. 1999 Mar 23;52(5):1072-4 Click [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10102433&query_hl=17&itool=pubmed_docsum here] to read
*MacDonald JK et al: ''Natalizumab for induction of remission in Crohn's disease''. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097. Click [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17253580&query_hl=19&itool=pubmed_docsum here] to read.
*Yousry TA et al: ''Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. ''N Engl J Med. 2006 Mar 2;354(9):924-33. Click [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16510746&query_hl=28&itool=pubmed_docsum here] to read.
''N Engl J Med. 2006 Mar 2;354(9):924-33. Click [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16510746&query_hl=28&itool=pubmed_docsum here] to read.
 
==Note==